Menu
 
Tuesday | Wednesday | Thursday | Friday | Saturday
WEDNESDAY, DECEMBER 9, 2015
7:00 am - 5:15 pm Registration - Bridge Hall  
     
7:00 am - 8:00 am Continental Breakfast - Hall C  
     
8:00 am - 8:15 am WELCOME AND OPENING REMARKS – Hall D  
     
8:15 am - 8:45 am PLENARY LECTURE 1 – Hall D  
     
 

Critical Decision Making in Radiation Therapy for Breast Cancer in 2015

 
 

Jay R. Harris, MD

Dana-Farber Cancer Institute

Boston, MA

 
     
8:45 am - 11:15 am

GENERAL SESSION 1 – Hall D

 
     
8:45 am S1-01.  Analysis of molecular prognostic factors associated with tumor immune and stromal microenvironment in BEATRICE, an open-label phase 3 trial in early triple-negative breast cancer (eTNBC)
 
 

Molinero L, Yu J, Li C, Deurloo R, Dent RA, Bell R, Brown J, Parmar M, Toi M, Suter T, Steger G, Pivot X, Mackey J, Jackisch C, Hall P, Hegde P, Bais C, Cameron D.   Genentech Inc., South San Francisco, CA; F Hoffmann-La Roche Ltd, Basel, Switzerland; National Cancer Center, Singapore, Singapore; Sunnybrook Health Sciences Center, University of Toronto, Toronto, Canada; Deakin University, Geelong, Australia; Clinical Trials Research Unit, University of Leeds, Leeds, United Kingdom; Medical Research Council Clinical Trials Unit, London, United Kingdom; Kyoto University, Kyoto, Japan; Swiss Cardiovascular Center, Bern University Hospital, Bern, Switzerland; Medical University of Vienna, Vienna, Austria; University Hospital Jean Minjoz, Besançon, France; Cross Center Institute, Edmonton, Canada; Klinikum Offenbach, Offenbach, Germany; Leeds Institute of Health Sciences, University of Leeds, Leeds, United Kingdom; University of Edinburgh and Cancer Services, NHS Lothian, Edinburgh, United Kingdom.

 
     
9:00 am

S1-02. Lymphocytic infiltration in invasive lobular breast cancer

 
  Desmedt C, Salgado R, Buisseret L, Zoppoli G, Fornili M, Van den Eynden G, Garaud S, Gundem G, Rothé F, Brown D, Kheddoumi N, Rouas G, Galant C, Bertucci F, Piccart M, Campbell P, Viale G, Larsimont D, Willard-Gallo K, Biganzoli E, Pruneri G, Sotiriou C.  Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium; University of Genoa, Genoa, Italy; University of Milan and Istituto Nazionale Tumori, Milan, Italy; Universiteit Antwerpen, Antwerp, Belgium; Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom; Université Catholique de Louvain, Brussels, Belgium; Institut Paoli-Calmettes, Marseille, France; European Institute of Oncology, Milan, Italy.
     
9:15 am S1-03. Pooled individual patient data analysis of stromal tumor infiltrating lymphocytes in primary triple negative breast cancer treated with anthracycline-based chemotherapy  
 

Loi S, Drubay D, Adams S, Francis PA, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Piccart MJ, Kellokumpa-Lehtinen P-L, Andre F, Dufaure-Gare I, Denkert C, Salgado R, Michiels S.  Peter MacCallum Cancer Centre, East Melbourne, Vic, Australia; Gustave Roussy, Villejuif, France; New York University School of Medicine, New York, NY; Helsinki University Central Hospital, Helsinki, Finland; University of Padova, Padova, Italy; Indiana University, Indianapolis, IN; Dana-Farber Cancer Institute, Boston, MA; Institut Jules Bordet, Brussels, Belgium; Tampere University Hospital, Tampere, Finland; Charite Universite Hospital, Berlin, Germany.

 
     
9:30 am

S1-04.  Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase Ib JAVELIN solid tumor trial

 
 

Dirix LY, Takacs I, Nikolinakos P, Jerusalem G, Arkenau H-T, Hamilton EP, von Heydebreck A, Grote H-J, Chin K, Lippman ME.  Sint Augustinus - University of Antwerp, Antwerp, Belgium; Semmelweis University, Budapest, Hungary; University Cancer & Blood Center, LLC, Athens, GA; CHU Sart Tilman Liege and Liege University, Liege, Belgium; Sarah Cannon Research Institute, London, United Kingdom; Sarah Cannon Research Institute, North Nashville, TN; Merck KGaA, Darmstadt, Germany; EMD Serono, Billerica, MA; University of Miami Miller School of Medicine, Miami, FL.

 
     
9:45 am S1-05.  Prophylactic beta blockade preserves left ventricular ejection fraction in HER2-overexpressing breast cancer patients receiving trastuzumab: Primary results of the MANTICORE randomized controlled trial 
 
 

Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, Thompson R, Oudit G, Ezekowitz J, Paterson I.  University of Alberta, Edmonton, AB, Canada; Cross Cancer Institute, Edmonton, AB, Canada; Mazankowski Alberta Heart Institute, Edmonton, AB, Canada; University of Manitoba, Winnipeg, MB, Canada; University of Texas, Arlington, TX.

 
     
10:00 am S1-06. The miR-424/503 cluster is a breast cancer tumor suppressor with a role in chemoresistance
 
 

Silva J, Llobet-Navas D, Rodriguez-Barrueco R, Sanchez-Garcia F, Pe'er D.  Mount Sinai School of Medicine, New York, NY; Columbia University, New York, NY.

 
     
10:15 am

S1-07. A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04)

 
 

Toi M, Lee S-J, Lee ES, Ohtani S, Im Y-H, Im S-A, Park B-W, Kim S-B, Yanagita Y, Takao S, Ohno S, Aogi K,  Iwata H, Kim A, Sasano H, Yokota I, Ohashi Y, Masuda N. Yeungnam University Hospital, Daegu, Korea; Kyoto University Hospital, Kyoto, Japan; National Cancer Center, Seoul, Korea; Hiroshima City Hospital, Hiroshima, Japan; Samsung Medical Center, Seoul, Korea; Seoul National University Hospital, Seoul, Korea; Severance Hospital, Yonsei University College of Medicine, Seoul Korea; Asan Medical Center, Seoul, Korea, Gunma Prefectural Cancer Center, Ota, Gunma, Japan; Hyogo Cancer Center, Akashi, Hyogo, Japan; National Kyusyu Cancer Center, Fukuoka, Japan; NHO Shikoku Cancer Center, Matsuyama, Ehime, Japan; Aichi Cancer Center, Nagoya, Aichi, Japan; Korea University Guro Hospital, Seoul, Korea; Tohoku University, Sendai, Miyagi, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Chuo University, Tokyo, Japan; NHO Osaka National Hospital, Osaka, Japan.

 
     
10:30 am

S1-08. High risk premenopausal luminal A breast cancer patients derive no benefit from adjuvant chemotherapy: results from DBCG77B randomized trial

 
 

Nielsen TO, Jensen M-B, Gao D, Leung S, Burugu S, Liu S, Tykjær Jørgensen CL, Balslev E, Ejlertsen B.  Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada; Danish Breast Cancer Cooperative Group, Copenhagen, Denmark; Genetic Pathology Evaluation Centre, Vancouver, BC, Canada; Canadian Immunohistochemistry Quality Control, Vancouver, BC, Canada; University of Ottawa, Ottawa, ON, Canada.

 
     
10:45 am S1-09.  A comparison of the diagnostic performance of 2D synthetic mammography versus digital breast tomosynthesis in 2500 patients  
  Sharaiha YM, Moalla A, Williams HR, Thomas D, Huws AM, Holt SD.  Prince Philip Hospital, Llanelli, Carmarthenshire, United Kingdom.  
     
11:00 am S1-10. Discussant  
  Emily Sedgwick, MD
Baylor College of Medicine
Houston, TX
 
     
11:15 am - 12:00 pm William L. McGuire Memorial Lecture - Hall D  
 

The Contribution of NSABP Clinical Trials to the Management of Early Breast Cancer

Norman Wolmark, MD

Allegheny General Hospital

Pittsburgh, PA
 
     
12:00 pm - 1:00 pm LUNCH AND EXHIBITS  
     
1:00 pm - 2:00 pm CLINICAL SCIENCE FORUM - Ballroom A  
 

Axillary Management in Primary Breast Cancer

Moderator: Ismail Jatoi, MD, PhD, FACS, UT Health Science Center, San Antonio, TX

 
 

Optimal management of the axilla: A look at the evidence

Eleftherios (Terry) P. Mamounas, MD, MPH, FACS

UF Health Cancer Center - Orlando Health

Orlando, FL

Contemporary role of radiotherapy in axillary management

Reshma Jagsi, MD, DPhil

University of Michigan Health System

Ann Arbor, MI
 
     
1:00 pm - 2:00 pm BASIC SCIENCE FORUM - Ballroom B  Supported by an educational grant from AstraZeneca  
 

Proteomic Analysis of Breast Cancer: Biological and Clinical Findings

Moderator: Rachel Schiff, PhD, Baylor College of Medicine, Houston, TX

 
 

Mass spectrometry-based proteomic and proteogenomic analyses of human breast cancer

Michael A. Gillette, MD, PhD

Broad Institute of MIT and Harvard

Cambridge, MA

Functional proteomics characterization of breast cancer

Gordon B. Mills, MD, PhD

UT MD Anderson Cancer Center

Houston, TX
 
  

2:15 pm - 3:15 pm

SUSAN G. KOMEN® BRINKER AWARDS FOR SCIENTIFIC DISTINCTION LECTURES – Hall D

 
  Susan G. Komen® Brinker Award for Scientific Distinction in Basic Science
Hacking the Hormone Code in ER+ Breast Cancer
Myles A. Brown, MD
Dana-Farber Cancer Institute
Boston, MA

Susan G. Komen® Brinker Award for Scientific Distinction in Clinical Investigation
Lessons learned from an expedition exploring the world of HER2 positive breast cancer
Martine Piccart, MD, PhD
Jules Bordet Institute
Brussels, BELGIUM
 
     
3:15 pm - 5:00 pm

GENERAL SESSION 2 – Hall D

 
     
3:15 pm S2-01.  Importance of margin width and re-excision in breast conserving treatment of early breast cancer; a Danish Breast Cancer Cooperative Group study of 11,900 women  
 

Bodilsen A, Bjerre K, Offersen BV, Vahl P, Mele M, Dixon MJ, Ejlertsen B, Overgaard J, Christiansen P.  Aarhus University Hospital, Aarhus, Denmark; Danish Breast Cancer Cooperative Group, Copenhagen, Denmark; Breakthrough Research Unit Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom.

 
     
3:30 pm S2-02. The impact of adjuvant denosumab on disease-free survival: Results from 3,425 postmenopausal patients of the ABCSG-18 trial  
 

Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, Wette V, Balic M, Haslbauer F, Melbinger E, Bjelic-Radisic V, Artner-Matuschek S,  Fitzal F, Marth C, Sevelda P, Mlineritsch B, Steger GG, Manfreda D, Exner R, Egle D, Bergh J, Kainberger F, Talbot S, Warner D, Fesl C, Singer CF, on behalf of the Austrian Breast and Colorectal Cancer Study Group.  Medical University of Vienna and Comprehensive Cancer Center, Vienna, Austria; Medical University Innsbruck, Innsbruck, Austria; Paracelsus Medical University Salzburg and Salzburg Cancer Research Institute, Salzburg, Austria; Breast Center/Doctor´s Office Wette, St. Veit/ Glan, Austria; Medical University Graz, Graz, Austria; Hospital Vöcklabruck, Vöcklabruck, Austria; Hospital Wolfsberg, Wolfsberg, Austria; Medical University Graz, Graz; Breast Center_ Hospital Hanusch-Vienna, Vienna, Austria; Hospital of Sisters of Mercy Linz/Breast Health Center, Linz, Austria; Hospital Hietzing, Vienna, Austria; Medical University of Vienna, Vienna, Austria; Doctor´s Office Manfreda, Klagenfurt, Austria; Karolinska Institute and University Hospital/Radiumhemmet, Karolinska Oncology, Stockholm, Sweden; Amgen Ltd, Uxbridge, United Kingdom; Amgen Inc, Thousand Oaks, CA; Austrian Breast & Colorectal Cancer Study Group, Vienna, Austria. 

 
     
3:45 pm S2-03. Persistence of circulating tumor cells in high risk early breast cancer patients during follow-up care suggests poor prognosis – results from the adjuvant SUCCESS A trial
 
 

Janni W, Rack B, Fasching P, Haeberle L, Friedl T, Tesch H, Lorenz R, Neugebauer J, Koch J, Jaeger B, Fehm T, Mueller V, Schneeweiß A, Lichtenegger W, Beckmann M, Scholz C, Pantel K, Trapp E.  University Hospital Ulm,University of Ulm, Ulm, Germany; University Hospital Ludwig-Maximilians University, Ludwig-Maximilians University, Munich, Germany; University Hospital, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany; Medical Center Hamburg-Eppendorf, University Hospital Hamburg-Eppendorf, Hamburg, Germany; University Hospital Heidelberg, Ruprecht-Karls-University, Heidelberg, Germany; University Hospital Nuremberg-Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Haemato-Oncology Practice, Bethanien Hospital, Frankfurt, Germany; Gynaecology Practice Lorenz/Hecker, Braunschweig, Germany; Charité University Hospital Campus Virchow, Berlin, Germany; University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

 
     
4:00 pm S2-04. Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto)  
 

von Minckwitz G, Loibl S, Schneeweiss A, Salat CT, Rezai M, Zahm D-M, Klare P, Blohmer J-U, Tesch H, Khandan F, Fasching PA, Jakisch C, Nekljudova V, Untch M.  German Breast Group, Neu-Isenburg, Germany; University Hospital Heidelberg, Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stoetzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; SRH Wald-Klinikum Gera, Gera, Germany; Praxisklinik Berlin, Berlin, Germany; Charité Breast Centre, Berlin, Germany; Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt, Germany; St. Markus Krankenhaus, Frankfurt, Germany; University Hospital Erlangen, Erlangen, Germany; Sana Klinikumk Offenbach, Offenbach, Germany; Helios Klinikum Berlin-Buch, Berlin, Germany.

 
     
4:15 pm S2-05. Event-free and overall survival following neoadjuvant weekly paclitaxel and dose-dense AC +/- carboplatin and/or bevacizumab in triple-negative breast cancer: outcomes from CALGB 40603 (Alliance)  
  Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Somlo G, Port ER, Qamar R, Sturtz K, Mamounas E, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey L, Hudis CA, Winer EP.  Program in Women's Oncology, Women and Infants Hospital of Rhode Island and Alpert Medical School of Brown University, Providence, RI; MD Anderson Cancer Center, Houston, TX; UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC; New York University Medical Center, New York, NY; Alliance Statistical Center, Durham, NC; Dana Farber Cancer Institute, Boston, MA; City of Hope Comprehensive Cancer Center, Duarte, CA; Mount Sinai Medical Center, New York, NY; Aurora Health Care NCORP, Milwaukee, WI; Colorado Cancer Research Program, Denver, CO; UF Health Cancer Center Orlando, Orlando, FL; Patient Advocates in Research, Danville, CA; University of Chicago Medical Center, Chicago, IL; Memorial Sloan Kettering Cancer Center, New York, NY; Brigham and Women's Hospital, Boston, MA.  
     
4:30 pm S2-06. Discussant  
  Angela M. DeMichele, MD, MSCE
University of Pennsylvania
Philadelphia, PA
 
     
4:45 pm S2-07. cfDNA analysis from BOLERO-2 plasma samples identifies a high rate of ESR1 mutations: Exploratory analysis for prognostic and predictive correlation of mutations reveals different efficacy outcomes of endocrine therapy-based regimens  
  Chandarlapaty S, Sung P, Chen D, He W, Samoila A, You D, Bhatt T, Patel P, Voi M, Gnant M, Hortobagyi G, Baselga J, Moynahan ME.  Memorial Sloan Kettering Cancer Center, New York, NY; Novartis Pharmaceuticals Corporation, East Hanover, NJ; Medical University of Vienna, Vienna, Austria; The University of Texas MD Anderson Cancer Center, Houston, TX.  
     
5:00 pm - 7:00 pm

POSTER DISCUSSION 1: Risk and Risk Reduction: Density, NSAIDS, Statins – Ballroom A

 
  Melissa L. Bondy, PhD, Co-Discussant
Baylor College of Medicine
Houston, TX
and
Powel H. Brown, MD, Co-Discussant
UT MD Anderson Cancer Center
Houston, TX
 
     
5:00 pm - 7:00 pm

POSTER DISCUSSION 2: Endocrine Therapies – Ballroom B  Supported by an educational grant from AstraZeneca

 
  Ingrid A. Mayer, MD, MSCI, Co-Discussant
Vanderbilt University Medical Center
Nashville, TN
and
Rachel Schiff, PhD, Co-Discussant
Baylor College of Medicine
Houston, TX
 
     
5:00 pm - 7:00 pm POSTER SESSION 1 & reception – Halls A-B
 
     
 

Detection/Diagnosis

Diagnostic Pathology 
Biopsy Techniques

P1-01
P1-02

     
 

Tumor Cell and Molecular Biology

Microenvironment - Stromal-Epithelial Interactions

Mammary Development and Differentiation

Epithelial-Mesenchymal Transition

Stem/Progenitor Cells

P1-03

P1-04

P1-05

P1-06

     
 

Epidemiology, Risk, and Prevention

Epidemiology - Population Studies

Epidemiology - Genetic and Molecular

Ethnic/Racial Aspects

P1-07

P1-08

P1-09

     
 

Psychosocial, Quality of Life, and Educational Aspects

Quality of Life - Supportive Care

Psychosocial Aspects

P1-10

P1-11

     
 

Treatment

Adjuvant Chemotherapy

Advanced Chemotherapy

Neoadjuvant Chemotherapy

Toxicities - Management

Treatment - Other

Rescheduled Posters

P1-12

P1-13

P1-14

P1-15

P1-16

     
  Ongoing Clinical Trials

Ongoing Trials - Immunotherapy
Ongoing Trials - CTCs
Ongoing Trials - Targeted Therapies


OT1-01
OT1-02
OT1-03
     
7:30 pm - 9:30 pm

OPEN SATELLITE EVENT presented by Research To Practice - Marriott Rivercenter, Grand Ballroom (3rd Floor)

Practical Application of Research Advances and Emerging Data in the Management of Breast Cancer

For more information or to register, please visit:
 http://www.researchtopractice.com/Meetings/SA2015

 
     
 
Tuesday | Wednesday | Thursday | Friday | Saturday